Genovate Biotechnology Co Ltd (4130) - Total Assets
Based on the latest financial reports, Genovate Biotechnology Co Ltd (4130) holds total assets worth NT$1.51 Billion TWD (≈ $47.46 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Genovate Biotechnology Co Ltd - Total Assets Trend (2015–2025)
This chart illustrates how Genovate Biotechnology Co Ltd's total assets have evolved over time, based on quarterly financial data. Also see Genovate Biotechnology Co Ltd stock valuation for the company's overall valuation and market capitalisation.
Genovate Biotechnology Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Genovate Biotechnology Co Ltd's total assets of NT$1.51 Billion consist of 47.8% current assets and 52.3% non-current assets. Review Genovate Biotechnology Co Ltd balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 11.2% |
| Accounts Receivable | NT$73.58 Million | 4.9% |
| Inventory | NT$143.83 Million | 9.6% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how Genovate Biotechnology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See 4130 share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genovate Biotechnology Co Ltd's current assets represent 47.8% of total assets in 2025, an increase from 38.4% in 2015.
- Cash Position: Cash and equivalents constituted 11.2% of total assets in 2025, up from 7.7% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is inventory at 9.6% of total assets.
Genovate Biotechnology Co Ltd Competitors by Total Assets
Key competitors of Genovate Biotechnology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Genovate Biotechnology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.74 | 5.61 | 4.02 |
| Quick Ratio | 4.59 | 4.54 | 3.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$593.98 Million | NT$628.97 Million | NT$484.79 Million |
Genovate Biotechnology Co Ltd - Advanced Valuation Insights
This section examines the relationship between Genovate Biotechnology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.76 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | -5.3% |
| Total Assets | NT$1.51 Billion |
| Market Capitalization | $115.03 Million USD |
Valuation Analysis
Below Book Valuation: The market values Genovate Biotechnology Co Ltd's assets below their book value (0.08x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Genovate Biotechnology Co Ltd's assets decreased by 5.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Genovate Biotechnology Co Ltd (2015–2025)
The table below shows the annual total assets of Genovate Biotechnology Co Ltd from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.51 Billion ≈ $47.46 Million |
-5.27% |
| 2024-12-31 | NT$1.59 Billion ≈ $50.10 Million |
-0.64% |
| 2023-12-31 | NT$1.60 Billion ≈ $50.42 Million |
+2.30% |
| 2022-12-31 | NT$1.56 Billion ≈ $49.29 Million |
+3.23% |
| 2021-12-31 | NT$1.52 Billion ≈ $47.75 Million |
-3.52% |
| 2020-12-31 | NT$1.57 Billion ≈ $49.49 Million |
-0.13% |
| 2019-12-31 | NT$1.57 Billion ≈ $49.56 Million |
-9.38% |
| 2018-12-31 | NT$1.74 Billion ≈ $54.69 Million |
-14.98% |
| 2017-12-31 | NT$2.04 Billion ≈ $64.33 Million |
-22.85% |
| 2016-12-31 | NT$2.65 Billion ≈ $83.37 Million |
+5.13% |
| 2015-12-31 | NT$2.52 Billion ≈ $79.31 Million |
-- |
About Genovate Biotechnology Co Ltd
Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medi… Read more